Simsen Diagnostics Announces Collaboration with Private Cancer Center Docrates

Gothenburg 2024-10-25: Simsen Diagnostics has signed an agreement with Docrates, a private cancer center in Finland. The agreement allows Docrates to use Simsen’s personalized ctDNA analysis for patient monitoring.

Docrates, a private cancer center based in Helsinki, Finland, is the only private cancer hospital in the Nordics. It offers personalized care throughout the entire patient journey, supported by leading experts in the field to ensure the highest quality of care. As part of the Mehiläinen Group, a well-known and respected private provider of social and healthcare services, Docrates is dedicated to adopting cutting-edge innovations to meet its patients’ needs and enhance their care.

Simsen Diagnostics’ solution, Simsen® Personal, is a highly sensitive, patient-specific test that detects circulating tumor DNA (ctDNA), a biomarker directly associated with the patient’s tumor. It tracks unique mutations to provide a detailed view of tumor dynamics. Using simple blood samples, the test monitors ctDNA levels over time, offering a minimally invasive way to detect even the smallest traces of cancer – potentially years before traditional methods.

Docrates recognizes the potential of this technology and the advantages of personalized tests in enhancing patient care. The goal is to utilize these assays for early detection of recurring cancer and residual disease, and for monitoring treatment effectiveness, including early indicators of response or resistance. A key aspect of this collaboration is achieving faster results compared to previous efforts. By integrating Simsen® Personal into Docrates’ practice, the solution can enable more personalized and optimized patient care, ultimately improving outcomes and increasing the chances of saving lives.

“We are pleased to integrate Simsen’s ctDNA analysis into our practice. This innovative technology aligns perfectly with Docrates’ commitment to providing personalized, cutting-edge cancer care. By leveraging the power of Simsen® Personal, we enhance our ability to monitor treatment responses and detect recurrences early, which will hopefully increase available treatment options and ultimately improve outcomes for our patients. This collaboration represents a significant advancement in our mission to deliver tailored care throughout the cancer journey.”

— Dr. Juha Kononen, Chief Clinical Director, Docrates Cancer Center

“The essence of Simsen Diagnostics is our commitment to a personalized approach in everything we do, from personalized assays to personalized customer service, which is very much in line with Docrates’ approach to providing personalized care. Our collaboration brings Simsen® Personal one step closer to patients, and we couldn’t be more excited about the opportunity to potentially improve their lives.”,

— Pontus Rehn, CEO, Simsen Diagnostics.

About Docrates

At Docrates Cancer Center, patients with cancer receive personalized care under one roof throughout their treatment and follow-up period. The hospital’s operations emphasize personalized and timely cancer treatments, alongside a commitment to quality, training, and research. Docrates operates a hospital in Helsinki, Finland, with a team of over 130 cancer care professionals. As a leading private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries. https://www.docrates.com/en/  

Docrates is part of Mehiläinen Group, a well-known and highly valued private provider of social and health care services, offering comprehensive high-quality services in Finland and internationally. Mehiläinen serves 2.1 million customers annually, and services are produced at 840 locations by more than 37,000 employees and private practitioners. Internationally, Mehiläinen provides healthcare services in Sweden, Germany, and Estonia, as well as digital healthcare software solutions through its subsidiary BeeHealthy. https://www.mehilainen.fi/en

About Simsen Daignostics

Simsen Diagnostics is a biotech startup focusing on transforming cancer monitoring. Specialized in designing patient-specific tests, Simsen® Personal, the flagship solution, is based on ultrasensitive sequencing technology capable of detecting cancer years before standard-of-care tools. Founded in 2020, as a research spin-out from Sahlgrenska Academy, Simsen Diagnostics has experienced steady growth, gaining recognition from e.g. the pharmaceutical industry. Situated in the BioVentureHub at AstraZeneca Gothenburg, the company is at the forefront of providing innovative solutions in cancer management and monitoring. https://simsendiagnostics.com/

One comment

  1. Heү! This is my first comment here so I just wanted to
    give a quick shout out and tell you I genuinely enjoy
    reading through your blog posts. Can you suggest any otһer blogѕ/ѡebsites/forums that cover tһe
    same topiϲs? Many thanks!

Leave a Reply

Your email address will not be published. Required fields are marked *

Pontus Rehn

Chief Executive Officer (CEO)

Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy. 

Lina Said

Laboratory and Quality Manager

Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab. 

My Vu

Lead Laboratory Technician

My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.  

Stefan Filges

Chief Technology Officer (CTO)

Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols. 

Camilla Hietanen

Head of Sales and Marketing

Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing. 

Almost there

Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.